Monoclonal Antibodies for Treatment of COVID-19

The Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) to allow the use of monoclonal antibody therapies for the treatment of mild to moderate symptoms of COVID-19 in certain high-risk patients.

What are monoclonal antibodies?
Monoclonal antibodies are laboratory-produced molecules that act as substitute antibodies that can restore, enhance, or mimic your immune system’s response. Monoclonal antibodies may neutralize or block the virus that causes COVID-19 from attaching to human cells thereby making it more difficult for the virus to reproduce and cause harm.

Monoclonal antibodies for COVID-19 are administered via intravenous (IV) infusion by medical professionals in outpatient settings to patients at high risk of requiring hospitalization.

Who is eligible for monoclonal antibody treatment?
You are eligible to be treated with monoclonal antibodies if you have mild to moderate symptoms of COVID-19, you have tested positive for COVID-19 within the last 10 days, and are:

- 65 years of age or older
- 55 years of age or older with:
  - Heart Disease
  - OR high blood pressure
  - OR COPD/chronic respiratory disease including asthma
- 12 years of age and older with:
  - A weakened immune system
  - OR you’re taking medicine that weakens your immune system
  - OR obesity (Body mass index of [BMI] of 35 or higher)
  - OR diabetes (type 1 of type 2)
  - OR chronic kidney disease
- 12 to 17 years of age and > 40kg (88 pounds) with:
  - Obesity (a BMI higher than 85 percent of patients the same age & gender)
  - OR Regularly uses medical technology such as a feeding tube or ventilator
  - OR has a developmental condition like cerebral palsy
  - OR sickle cell disease
  - OR congenital or acquired heart disease
  - OR asthma/chronic respiratory problems requiring daily medication

Where can you receive monoclonal antibody treatment?
Patients who test positive for COVID-19 should talk to their healthcare provider about eligibility and treatment options. NC DHHS has worked with the National Infusion Center Association (NICA) to include North Carolina locations offering monoclonal antibody treatment on their COVID-19 Infusion Center Locator Tool.

For more information:
HHS COMBAT COVID website
NICA COVID-19 Antibody Therapy Resource Center
Product-specific fact sheets for patients and caregivers: Bamlanivimab, Casirivimab/Imdevimab & Bamlanivimab/Etesevimab.